Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

Despite considerable global investment, only 60% of people who live with HIV currently
receive antiretroviral therapy. The sustainability of current programmes remains unknown …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

HIV-1-infected cells that persist despite antiretroviral therapy (ART) are frequently
considered" transcriptionally silent," but active viral gene expression may occur in some …

Sustained, drug-free control of HIV-1 replication is naturally achieved in less than 0.5% of
infected individuals (here termed 'elite controllers'), despite the presence of a replication …

Background Antiretroviral therapy (ART) halts HIV-1 replication, decreasing viremia to below
the detection limit of clinical assays. However, some individuals experience persistent …

BACKGROUND Understanding HIV dynamics across the human body is important for cure
efforts. This goal has been hampered by technical difficulties and the challenge of obtaining …

BACKGROUND The relative stabilities of the intact and defective HIV genomes over time
during effective antiretroviral therapy (ART) have not been fully characterized. METHODS …

Despite long-term antiretroviral therapy (ART), HIV-1 persists within a reservoir of CD4+ T
cells that contribute to viral rebound if treatment is interrupted. Identifying the cellular …

Although antiretroviral therapy (ART) is highly effective at suppressing HIV-1 replication, the
virus persists as a latent reservoir in resting CD4+ T cells during therapy. This reservoir …